Cypherpunk Technologies (NASDAQ:CYPH) Announces Quarterly Earnings Results

Cypherpunk Technologies (NASDAQ:CYPH) announced its quarterly earnings results on Monday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.42), FiscalAI reports.

Cypherpunk Technologies Stock Performance

Cypherpunk Technologies stock opened at $1.09 on Wednesday. The stock’s 50 day moving average price is $0.86 and its two-hundred day moving average price is $1.00. Cypherpunk Technologies has a 52-week low of $0.23 and a 52-week high of $3.70. The stock has a market capitalization of $116.04 million, a price-to-earnings ratio of -54.47 and a beta of -0.09.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on CYPH shares. Wall Street Zen cut shares of Cypherpunk Technologies from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings upgraded Cypherpunk Technologies from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, April 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Hedge Funds Weigh In On Cypherpunk Technologies

Institutional investors have recently made changes to their positions in the stock. Millennium Management LLC acquired a new position in shares of Cypherpunk Technologies during the fourth quarter valued at about $37,000. LPL Financial LLC bought a new stake in shares of Cypherpunk Technologies during the fourth quarter valued at approximately $38,000. HighTower Advisors LLC bought a new stake in shares of Cypherpunk Technologies during the fourth quarter valued at approximately $59,000. State Street Corp bought a new stake in shares of Cypherpunk Technologies during the fourth quarter valued at approximately $163,000. Finally, Geode Capital Management LLC bought a new stake in shares of Cypherpunk Technologies during the fourth quarter valued at approximately $615,000. Institutional investors and hedge funds own 30.46% of the company’s stock.

About Cypherpunk Technologies

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.